zadoprubart

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
zadoprubart

GtoPdb Ligand ID: 13799

Compound class: Antibody

Comment: Zadoprubart is the INN for an anti-B and T lymphocyte attenuator (BTLA) monoclonal antibody. We have been unable to associate this with a clinical candidate or company research code.

There is information confirming two anti-BTLA monoclonals that were progressed to clinical development: HFB200603 (HiFiBiO; Phase 1 NCT05789069, solid tumours) [2] and ANB032 (AnaptysBio; Phase 2 NCT05935085, atopic dermatitis; terminated due to insufficient efficacy) [1].

References
1. Dahl M, Hsu M, Schendel C, Haines C, Soroosh P, Parmley S, Hare E. (2024) ANB032, a novel BTLA agonist monoclonal antibody, reduced T cell proliferation, inflammatory cytokine secretion and prevented graft versus host disease in a mouse model. J Immunology, 212 ((1_Supplement)). DOI: 10.4049/jimmunol.212.supp.0518.5691
2. hifibio. HFB200603: BTLA Antagonist. Accessed on 11/03/2025. Modified on 11/03/2025. hifibio.com, https://hifibio.com/pipeline/programs/hfb200603/

References

1. Dahl M, Hsu M, Schendel C, Haines C, Soroosh P, Parmley S, Hare E. (2024)
ANB032, a novel BTLA agonist monoclonal antibody, reduced T cell proliferation, inflammatory cytokine secretion and prevented graft versus host disease in a mouse model.
J Immunology, 212 ((1_Supplement)). DOI: 10.4049/jimmunol.212.supp.0518.5691

2. hifibio.
HFB200603: BTLA Antagonist.
Accessed on 11/03/2025. Modified on 11/03/2025. hifibio.com, https://hifibio.com/pipeline/programs/hfb200603/